What do systematic reviews say?

Summary of findings ‐ Inhaled mannitol plus dornase alfa vs dornase alfa

• Inhaled mannitol for cystic fibrosis 2020 · Cochrane Headline outcomes only
  no estimate extracted
  231 participants
  Very low

Summary of findings ‐ Inhaled mannitol plus dornase alfa vs dornase alfa

It is very uncertain whether summary of findings ‐ Inhaled mannitol plus dornase alfa changes lung function: FEV1mL (percentage change from baseline) compared with dornase alfa (very low certainty).

• Inhaled mannitol for cystic fibrosis 2020 · Cochrane Headline outcomes only
  no estimate extracted
  231 participants
  Very low

Summary of findings ‐ Inhaled mannitol plus dornase alfa vs dornase alfa

The review found no eligible studies for this question.

• Inhaled mannitol for cystic fibrosis 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings ‐ Inhaled mannitol plus dornase alfa vs dornase alfa

It is very uncertain whether summary of findings ‐ Inhaled mannitol plus dornase alfa changes lung function: FVC mL (percentage change from baseline) compared with dornase alfa (very low certainty).

• Inhaled mannitol for cystic fibrosis 2020 · Cochrane Headline outcomes only
  no estimate extracted
  231 participants
  Very low

Summary of findings ‐ Inhaled mannitol plus dornase alfa vs dornase alfa

It is very uncertain whether summary of findings ‐ Inhaled mannitol plus dornase alfa changes lung function: FEF25-75 mL/s (percentage change from baseline) compared with dornase alfa (very low certainty).

• Inhaled mannitol for cystic fibrosis 2020 · Cochrane Headline outcomes only
  no estimate extracted
  231 participants
  Very low

Summary of findings ‐ Inhaled mannitol plus dornase alfa vs dornase alfa

• Inhaled mannitol for cystic fibrosis 2020 · Cochrane Headline outcomes only
  no estimate extracted
  231 participants
  Very low